| Literature DB >> 32501276 |
Margalida Gili1,2,3, Adoración Castro1,2, Azucena García-Palacios4,5, Javier Garcia-Campayo3,6, Fermin Mayoral-Cleries7, Cristina Botella4,5, Miquel Roca1,2,3, Alberto Barceló-Soler8, María M Hurtado7, MªTeresa Navarro9, Amelia Villena10, M Ángeles Pérez-Ara1,2, Pau Riera-Serra1,2, Rosa Mª Baños5,11.
Abstract
BACKGROUND: Primary care is a major access point for the initial treatment of depression, but the management of these patients is far from optimal. The lack of time in primary care is one of the major difficulties for the delivery of evidence-based psychotherapy. During the last decade, research has focused on the development of brief psychotherapy and cost-effective internet-based interventions mostly based on cognitive behavioral therapy (CBT). Very little research has focused on alternative methods of treatment for depression using CBT. Thus, there is a need for research into other therapeutic approaches.Entities:
Keywords: depression; internet-based interventions; primary care; randomized controlled trial
Mesh:
Year: 2020 PMID: 32501276 PMCID: PMC7305559 DOI: 10.2196/15845
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Intervention modules and main objectives.
| Intervention and modules | Main objective | |
|
| ||
|
| Beginning of a lifestyle change | To teach the importance of healthy lifestyle to improve emotional health and general well-being and to give structured hygienic-dietary recommendations. |
|
| Physical activity. Learning to move on | To give information about the most recommended exercises to improve mood, and to train the patient in learning procedures to increase motivation, to start being more active, and to maintain this physical activity regularly. |
|
| Diet. Learning to eat | To teach the importance of diet to achieve a good physical and mental health, and the role of the Mediterranean diet in the prevention and treatment of depression. |
|
| Sleep. The importance of good sleep | To understand the relationship between sleep and general health. |
|
| ||
|
| Learning to live | To teach the importance of establishing and maintaining an adequate activity level and the relevance of choosing activities that are significant, with a personal meaning for the individual. |
|
| Learning to enjoy | To give education about the effect of positive emotions and to train the patient in learning procedures to increase the likelihood of experiencing positive emotions, promoting the occurrence of pleasant activities to learn to enjoy the present moment. |
|
| Accepting to life | To train the patient in focusing on positive emotions related with the past (such as gratitude) or the future (such as optimism). |
|
| Living and learning | To train the patient in understanding life as a continuous process of learning and personal growth, emphasizing the training in strategies to promote psychological strengths, resilience, and meaningful goals linked to important values. |
|
| ||
|
| Getting to know mindfulness | To show what mindfulness is, prejudices about it, the inattention problem, and some of its main benefits and recommendations to practice it. |
|
| Establishing formal and informal practices | To teach the importance of the establishment not only of formal but also of informal practice. |
|
| Through management, body scan practice and values | To help people to see the importance of values to keep a regular mindfulness practice. |
|
| Self-compassion. Integrating mindfulness in everyday life | To establish a regular practice of mindfulness to be indefinitely kept. |
Figure 1Flow diagram.
Baseline characteristics of participants between intervention groups.
| Intervention characteristics and measures | Intervention groups | |||||
|
| iTAUa | HLPb | MPc | PAPPd | ||
|
| ||||||
|
| Age, mean (SD) | 44.54 (16.10) | 44.67 (9.98) | 47.50 (13.09) | 44.53 (10.23) | |
|
| Sex (female), n (%) | 41 (72) | 40 (74) | 47 (87) | 44 (79) | |
|
| Married, n (%) | 24 (52) | 23 (47) | 27 (59) | 31 (62) | |
|
| Living with family or couple, n (%) | 38 (83) | 36 (75) | 34 (76) | 44 (88) | |
|
| High education, n (%) | 14 (33) | 18 (45) | 17 (43) | 19 (40) | |
|
|
| 20 (44) | 22 (47) | 17 (40) | 25 (50) | |
|
|
| <1 NMWe | 6 (19) | 10 (30) | 7 (23) | 13 (33) |
|
|
| 1-2 NMW | 16 (52) | 16 (48) | 7 (23) | 14 (36) |
|
|
| 2-4 NMW | 8 (26) | 7 (21) | 12 (40) | 12 (31) |
|
|
| >4 NMW | 1 (3) | 0 (0) | 4 (13) | 0 (0) |
|
| ||||||
|
|
| |||||
|
|
| PHQ-9f, mean (SD); median (IQR) | 12.46 (2.10); 13.0 (11-14) | 12.57 (2.46); 13.5 (11-14) | 12.67 (2.56); 13.0 (11-14) | 12.63 (2.03); 13.0 (11.5-14) |
|
|
| |||||
|
|
| Physical SF-12g, mean (SD); median (IQR) | 43.06 (11.03); 41.38 (35.49-51.89) | 42.16 (10.66); 39.84 (35.07-52.02) | 42.52 (9.75); 42.11 (35.58-48.27) | 45.17 (13.54); 45.74 (35.04-55.65) |
|
|
| Mental SF-12, mean (SD); median (IQR) | 26.75 (9.62); 24.54 (20.97-30.58) | 27.59 (9.61); 25.98 (21.47-32.75) | 26.96 (10.86); 24.51 (20.93-28.66) | 26.22 (9.97); 23.79 (19.77-29.85) |
|
|
| VAS EuroQolh, mean (SD); median (IQR) | 51.60 (17.95); 50 (40-60) | 52.22 (21.63); 50 (30-70) | 48.91 (26.01); 50 (30-70) | 49.00 (19.05); 50 (40-60) |
|
|
| Overall PHIi index, mean (SD); median (IQR) | 4.3 (1.86); 4.33 (2.92-5.42) | 4.4 (1.95); 4.42 (3-5.42) | 4.32 (1.83); 4.42 (2.96-5.17) | 4.25 (1.98); 4.58 (2.83-5.42) |
|
|
| Positive affect PANASj, mean (SD); median (IQR) | 18.56 (6.43); 17 (14-23) | 19.04 (6.94); 18 (13-25) | 19.48 (6.60); 18 (15-22) | 18.09 (6.00); 17 (13-22) |
|
|
| Negative affect PANAS, mean (SD); median (IQR) | 28.27 (8.45); 27 (22-34) | 28.91 (8.34); 29 (23-35) | 27.89 (8.07); 27 (22-32.75) | 29.46 (8.79); 27 (23-35.5) |
aiTAU: improved treatment as usual.
bHLP: healthy lifestyle program.
cMP: mindfulness program.
dPAPP: positive affect promotion program.
eNMW: national minimum wage.
fPHQ-9: Patient Health Questionnaire-9 items.
gSF-12: 12-item Short-Form Health Survey.
hVAS EuroQol: visual analog scale of the EuroQol.
iPHI: Pemberton Happiness Index.
jPANAS: Positive and Negative Affect Schedule.
Primary outcome analysis with imputed data (N=221): intervention comparisons along the follow-up.
| Primary outcome | Time 1 (pretreatment) | Time 2 (posttreatment) | Time 3 (6 months) | Time 4 (12 months) | ||||||
|
| ||||||||||
|
|
| |||||||||
|
|
| gd | 0.25 | –0.50 | –0.22 | –0.06 | ||||
|
|
| .20 |
| .23 | .73 | |||||
|
|
| βf (95% CI) | 1.41 (–0.75 to 3.57) | –3.05 (–5.43 to –0.68) | –1.52 (–3.98 to 0.95) | –0.40 (–2.71 to 1.91) | ||||
|
|
| |||||||||
|
|
| g | –0.17 | 0.47 | 0.24 | –0.01 | ||||
|
|
| .36 | . | .18 | .96 | |||||
|
|
| β (95% CI) | 1.00 (–1.16 to 3.16) | –3.00 (–5.37 to –0.63) | –1.68 (–4.15 to 0.78) | 0.06 (–2.25 to 2.37) | ||||
|
|
| |||||||||
|
|
| g | –0.23 | 0.23 | 0.31 | 0.01 | ||||
|
|
| .20 | .22 | .10 | .99 | |||||
|
|
| β (95% CI) | 1.40 (–0.74 to 3.54) | –1.46 (–3.81 to 0.89) | –2.08 (–4.52 to 0.37) | –0.02 (–2.31 to 2.27) | ||||
|
|
| |||||||||
|
|
| g | 0.07 | -0.01 | 0.03 | –0.07 | ||||
|
|
| .71 | .96 | .90 | .70 | |||||
|
|
| β (95% CI) | 0.41 (–1.78 to 2.57) | –0.06 (–2.46 to 2.35) | 0.17 (–2.33 to 2.67) | –0.46 (–2.81 to 1.88) | ||||
|
|
| |||||||||
|
|
| g | 0.00 | –0.25 | 0.09 | –0.06 | ||||
|
|
| .99 | .19 | .66 | .75 | |||||
|
|
| β (95% CI) | 0.01 (–2.16 to 2.18) | –1.59 (–3.97 to 0.79) | 0.56 (–1.92 to 3.04) | –0.38 (–2.70 to 1.94) | ||||
|
|
| |||||||||
|
|
| g | –0.07 | –0.23 | 0.06 | 0.01 | ||||
|
|
| .72 | .21 | .76 | .94 | |||||
|
|
| β (95% CI) | 0.40 (–1.77 to 2.57) | 1.53 (–0.85 to 3.92) | –0.39 (–2.87 to 2.08) | –0.08 (–2.41 to 2.24) | ||||
aPHQ-9: Patient Health Questionnaire-9 items.
biTAU: improved treatment as usual.
cHLP: healthy lifestyle program.
dg: Hedge’s effect size measure.
eStatistically significant values (P<.05) are shown in italics.
fβ: regression coefficient.
gMP: mindfulness program.
hPAPP: positive affect promotion program.
Dose-response in imputed primary outcome at posttreatment and along the follow-up.
| Interventions | Pretreatment to posttreatment | Pretreatment to posttreatment | Pretreatment to posttreatment | ||||||||||
|
| βa (95% CI) | β (95% CI) | β (95% CI) | ||||||||||
|
| |||||||||||||
|
| CACEc analysisd | –3.32 (4.43 to –2.21) |
| –0.51 (2.03 to 1.02) | .74 | –1.03 (2.61 to 0.56) | .52 | ||||||
|
| Effect per session | –0.28 (0.34 to –0.21) |
| –0.17 (0.25 to –0.09) |
| –0.06 (0.13 to 0.02) | .45 | ||||||
|
| |||||||||||||
|
| CACE analysis | 0.93 (0.71 to 2.57) | .57 | 1.01 (0.72 to 2.74) | .56 | 1.13 (0.5 to 2.76) | .49 | ||||||
|
| Effect per session | 0.26 (0.22 to 0.74) | .59 | –0.17 (0.25 to –0.09) |
| –0.06 (0.13 to 0.02) | .45 | ||||||
|
| |||||||||||||
|
| CACE analysis | 0.24 (1.30 to 1.78) | .88 | 0.96 (0.66 to 2.57) | .56 | 0.30 (1.24 to 1.84) | .85 | ||||||
|
| Effect per session | –0.28 (0.34 to –0.21) | . | –0.17 (0.25 to –0.09) |
| –0.06 (0.13 to 0.02) | .45 | ||||||
|
| |||||||||||||
|
| CACE analysis | –2.11 (2.86 to –1.36) |
| –0.49 (1.37 to 0.4) | .58 | –0.22 (1.04 to 0.6) | .79 | ||||||
|
| Effect per session | –0.28 (0.34 to –0.21) |
| –0.17 (0.25 to –0.09) |
| –0.06 (0.13 to 0.02) | .45 | ||||||
aβ: regression coefficients.
bHLP: healthy lifestyle program.
cCACE: Complier Average Causal Effect.
dCompliance as attendance >4 modules.
eStatistically significant values (P<.05) are shown in italics.
fMP: mindfulness program.
gPAPP: positive affect promotion program..
Short-Form Health Survey-12 (Mental and Physical) outcome analysis with imputed data (N=221): intervention comparisons along the follow-up.
| Secondary outcomes | Time 1 (pretreatment) | Time 2 (posttreatment) | Time 3 (6 months) | Time 4 (12 months) | |||||
|
| |||||||||
|
|
| ||||||||
|
|
| gd | –0.06 | –0.42 | –0.11 | 0.01 | |||
|
|
| .73 | . | .53 | .98 | ||||
|
|
| βf (95% CI) | –0.63 (–4.25 to 2.99) | –5.32 (–9.91 to –0.72) | –1.53 (–6.30 to 3.23) | –0.05 (–5.04 to 4.93) | |||
|
|
| ||||||||
|
|
| g | 0.14 | 0.16 | 0.01 | –0.05 | |||
|
|
| .46 | .38 | .94 | .81 | ||||
|
|
| β (95% CI) | –1.37 (–4.99 to 2.24) | –2.06 (–6.66 to 2.53) | –0.18 (–4.95 to 4.58) | 0.62 (–4.36 to 5.61) | |||
|
|
| ||||||||
|
|
| g | 0.15 | 0.67 | 0.22 | 0.24 | |||
|
|
| .45 |
| .28 | .20 | ||||
|
|
| β (95% CI) | –1.37 (–4.96 to 2.21) | –7.72 (–12.27 to –3.16) | –2.61 (–7.33 to 2.11) | –3.2 (–8.14 to 1.74) | |||
|
|
| ||||||||
|
|
| g | 0.07 | –0.25 | –0.1 | –0.05 | |||
|
|
| .69 | .17 | .58 | .79 | ||||
|
|
| β (95% CI) | –0.74 (–4.41 to 2.93) | 3.25 (–1.41 to 7.91) | 1.35 (–3.48 to 6.18) | 0.68 (–4.37 to 5.73) | |||
|
|
| ||||||||
|
|
| g | 0.01 | 0.17 | –0.07 | –0.12 | |||
|
|
| .97 | .38 | .72 | .49 | ||||
|
|
| β (95% CI) | –0.07 (–4.22 to 4.08) | –2.04 (–6.59 to 2.51) | 0.76 (–3.41 to 4.92) | 1.36 (–2.51 to 5.24) | |||
|
|
| ||||||||
|
|
| g | 0.23 | 0.23 | 0.25 | 0.09 | |||
|
|
| .20 | .23 | .23 | .62 | ||||
|
|
| β (95% CI) | –2.72 (–6.87 to 1.43) | –2.77 (–7.32 to 1.78) | –2.53 (–6.69 to 1.64) | –0.97 (–4.85 to 2.9) | |||
|
| |||||||||
|
|
| ||||||||
|
|
| g | 0.04 | 0.37 | 0.39 | –0.19 | |||
|
|
| .86 | . |
| .35 | ||||
|
|
| β (95% CI) | 0.36 (–3.77 to 4.5) | 4.58 (0.05 to 9.11) | 4.73 (0.58 to 8.87) | –1.85 (–5.7 to 2.01) | |||
|
|
| ||||||||
|
|
| g | –0.25 | –0.42 | –0.73 | –0.05 | |||
|
|
| .15 |
| . | .80 | ||||
|
|
| β (95% CI) | 3.01 (–1.12 to 7.14) | 5.32 (0.79 to 9.85) | 8.01 (3.87 to 12.16) | 0.49 (–3.37 to 4.35) | |||
|
|
| ||||||||
|
|
| g | –0.03 | –0.21 | –0.50 | 0.05 | |||
|
|
| .89 | .27 |
| .80 | ||||
|
|
| β (95% CI) | 0.29 (–3.8 to 4.39) | 2.54 (–1.94 to 7.03) | 5.49 (1.38 to 9.6) | –0.48 (–4.3 to 3.34) | |||
|
|
| ||||||||
|
|
| g | –0.22 | –0.06 | –0.29 | –0.21 | |||
|
|
| .21 | .75 | .13 | .24 | ||||
|
|
| β (95% CI) | 2.65 (–1.54 to 6.83) | 0.73 (–3.86 to 5.32) | 3.28 (–0.92 to 7.49) | 2.34 (–1.57 to 6.25) | |||
|
|
| ||||||||
|
|
| g | 0.08 | 0.20 | 0.09 | 0.23 | |||
|
|
| .69 | .31 | .66 | .22 | ||||
|
|
| β (95% CI) | –0.74 (–4.37 to 2.9) | –2.4 (–7.02 to 2.22) | –1.08 (–5.86 to 3.71) | –3.15 (–8.15 to 1.86) | |||
|
|
| ||||||||
|
|
| g | 0.01 | 0.47 | 0.20 | 0.28 | |||
|
|
| >.99 | . | .32 | .13 | ||||
|
|
| β (95% CI) | 0.01 (–3.63 to 3.64) | –5.65 (–10.27 to –1.03) | –2.43 (–7.21 to 2.36) | –3.82 (–8.83 to 1.18) | |||
aSF-12: 12-item Short-Form Health Survey.
biTAU: improved treatment as usual.
cHLP: healthy lifestyle program.
dg: Hedge’s effect size measure.
eStatistically significant values (P<.05) are shown in italics.
fβ: regression coefficient.
gMP: mindfulness program.
hPAPP: positive affect promotion program.
Visual analog scale of the EuroQol and Pemberton Happiness Index outcome analysis with imputed data (N=221): intervention comparisons along the follow-up.
| Secondary outcomes | Time 1 (pretreatment) | Time 3 (6 months) | Time 4 (12 months) | ||
|
| |||||
|
|
| ||||
|
|
| gd | 0.02 | –0.20 | –0.33 |
|
|
| .91 | .31 | .08 | |
|
|
| βe (95% CI) | 0.47 (–7.93 to 8.87) | –3.82 (–11.17 to 3.53) | –6.56 (–13.86 to 0.75) |
|
|
| ||||
|
|
| g | 0.17 | 0.18 | 0.16 |
|
|
| .33 | .33 | .39 | |
|
|
| β (95% CI) | –4.16 (–12.56 to 4.24) | –3.63 (–10.98 to 3.72) | –3.17 (–10.47 to 4.14) |
|
|
| ||||
|
|
| g | 0.18 | 0.10 | 0.09 |
|
|
| .36 | .60 | .63 | |
|
|
| β (95% CI) | –3.9 (–12.22 to 4.43) | –1.95 (–9.23 to 5.33) | –1.76 (–9.00 to 5.48) |
|
|
| ||||
|
|
| g | 0.19 | –0.01 | –0.17 |
|
|
| .29 | .96 | .58 | |
|
|
| β (95% CI) | –4.63 (–13.14 to 3.88) | 0.19 (–7.26 to 7.63) | –2.04 (–9.21 to 5.2) |
|
|
| ||||
|
|
| g | 0.21 | –0.10 | –0.24 |
|
|
| .31 | .62 | .20 | |
|
|
| β (95% CI) | –4.37 (–12.8 to 4.07) | 1.86 (–5.52 to 9.24) | 4.79 (–2.55 to 12.13) |
|
|
| ||||
|
|
| g | –0.01 | –0.08 | –0.07 |
|
|
| .95 | .65 | .71 | |
|
|
| β (95% CI) | 0.26 (–8.17 to 8.7) | 1.68 (–5.7 to 9.06) | 1.4 (–5.93 to 8.74) |
|
| |||||
|
|
| ||||
|
|
| g | –0.05 | 0.19 | –0.18 |
|
|
| .81 | .30 | .33 | |
|
|
| β (95% CI) | –0.09 (–0.79 to 0.61) | 0.40 (–0.35 to 1.16) | –0.32 (–0.98 to 0.33) |
|
|
| ||||
|
|
| g | 0.08 | –0.49 | –0.06 |
|
|
| .65 | . | .75 | |
|
|
| β (95% CI) | –0.16 (–0.86 to 0.54) | 0.98 (0.22 to 1.73) | 0.11 (–0.55 to 0.77) |
|
|
| ||||
|
|
| g | 0.10 | –0.42 | 0.09 |
|
|
| .59 | . | .61 | |
|
|
| β (95% CI) | –0.19 (–0.89 to 0.5) | 0.82 (0.07 to 1.57) | –0.17 (–0.82 to 0.48) |
|
|
| ||||
|
|
| g | 0.04 | –0.27 | –0.25 |
|
|
| .84 | .14 | .20 | |
|
|
| β (95% CI) | –0.07 (–0.78 to 0.64) | 0.57 (–0.19 to 1.34) | 0.43 (–0.23 to 1.1) |
|
|
| ||||
|
|
| g | 0.06 | –0.2 | –0.08 |
|
|
| .77 | .28 | .65 | |
|
|
| β (95% CI) | –0.11 (–0.81 to 0.6) | 0.42 (–0.34 to 1.17) | 0.15 (–0.51 to 0.81) |
|
|
| ||||
|
|
| g | 0.02 | 0.08 | 0.16 |
|
|
| .93 | .68 | .41 | |
|
|
| β (95% CI) | –0.03 (–0.74 to 0.67) | –0.16 (–0.92 to 0.6) | –0.28 (–0.94 to 0.38) |
aVAS EuroQol: visual analog scale of the EuroQol.
biTAU: improved treatment as usual.
cHLP: healthy lifestyle program.
dg: Hedge’s effect size measure.
eβ: regression coefficient.
fMP: mindfulness program.
gPAPP: positive affect promotion program.
hPHI: Pemberton Happiness Index.
iStatistically significant values (P<.05) are shown in italics.
Positive and Negative Affect Scales outcome analysis with imputed data (N=221): intervention comparisons along the follow-up.
| Secondary outcomes | Time 1 (pretreatment) | Time 2 (posttreatment) | Time 3 (6 months) | Time 4 (12 months) | ||||||
|
| ||||||||||
|
|
| |||||||||
|
|
| gd | 0.07 | –0.01 | 0.25 | 0.34 | ||||
|
|
| .72 | .94 | .17 | .07 | |||||
|
|
| βe (95% CI) | 0.45 (–1.96 to 2.85) | –0.12 (–3.47 to 3.23) | 2.24 (–1.00 to 5.48) | 3.36 (–0.30 to 7.01) | ||||
|
|
| |||||||||
|
|
| g | 0.14 | 0.00 | –0.16 | –0.33 | ||||
|
|
| .44 | >.99 | .41 | .09 | |||||
|
|
| β (95% CI) | –0.94 (–3.35 to 1.46) | –0.01 (–3.36 to 3.34) | 1.35 (–1.88 to 4.59) | 3.19 (–0.46 to 6.85) | ||||
|
|
| |||||||||
|
|
| g | 0.21 | 0.31 | 0.05 | –0.15 | ||||
|
|
| .25 | .10 | .81 | .41 | |||||
|
|
| β (95% CI) | –1.41 (–3.79 to 0.97) | –2.78 (–6.09 to 0.54) | –0.40 (–3.61 to 2.81) | 1.51 (–2.11 to 5.13) | ||||
|
|
| |||||||||
|
|
| g | 0.22 | –0.01 | 0.10 | 0.02 | ||||
|
|
| .26 | .95 | .59 | .93 | |||||
|
|
| β (95% CI) | –1.39 (–3.83 to 1.05) | 0.11 (–3.28 to 3.5) | –0.89 (–4.17 to 2.39) | –0.17 (–3.87 to 3.54) | ||||
|
|
| |||||||||
|
|
| g | 0.29 | 0.31 | 0.3 | 0.19 | ||||
|
|
| .13 | .12 | .11 | .32 | |||||
|
|
| β (95% CI) | –1.86 (–4.27 to 0.56) | –2.66 (–6.02 to 0.71) | –2.64 (–5.89 to 0.61) | –1.85 (–5.52 to 1.82) | ||||
|
|
| |||||||||
|
|
| g | 0.08 | 0.33 | 0.21 | 0.17 | ||||
|
|
| .70 | .11 | .29 | .37 | |||||
|
|
| β (95% CI) | –0.47 (–2.88 to 1.95) | –2.77 (–6.13 to 0.59) | –1.75 (–5.00 to 1.5) | –1.68 (–5.35 to 1.99) | ||||
|
| ||||||||||
|
|
| |||||||||
|
|
| g | –0.12 | –0.32 | –0.16 | –0.36 | ||||
|
|
| .52 | .09 | .39 | .07 | |||||
|
|
| β (95% CI) | –1.02 (–4.18 to 2.14) | –2.81 (–6.04 to 0.42) | –1.37 (–4.51 to 1.78) | –3.15 (–6.51 to 0.21) | ||||
|
|
| |||||||||
|
|
| g | –0.06 | 0.31 | 0.16 | 0.24 | ||||
|
|
| .73 | .10 | .40 | .18 | |||||
|
|
| β (95% CI) | 0.55 (–2.61 to 3.71) | –2.73 (–5.96 to 0.5) | –1.35 (–4.49 to 1.80) | –2.32 (–5.67 to 1.04) | ||||
|
|
| |||||||||
|
|
| g | 0.25 | 0.31 | 0.33 | 0.41 | ||||
|
|
| .19 | .11 | .11 |
| |||||
|
|
| β (95% CI) | –2.09 (–5.22 to 1.04) | –2.59 (–5.79 to 0.61) | –2.54 (–5.65 to 0.57) | –3.63 (–6.96 to –0.31) | ||||
|
|
| |||||||||
|
|
| g | –0.19 | –0.01 | 0.00 | –0.09 | ||||
|
|
| .33 | .96 | .99 | .63 | |||||
|
|
| β (95% CI) | 1.57 (–1.63 to 4.78) | 0.07 (–3.20 to 3.35) | 0.02 (–3.17 to 3.20) | 0.83 (–2.57 to 4.23) | ||||
|
|
| |||||||||
|
|
| g | 0.13 | –0.03 | 0.14 | 0.06 | ||||
|
|
| .51 | .90 | .46 | .78 | |||||
|
|
| β (95% CI) | –1.07 (–4.24 to 2.11) | 0.21 (–3.03 to 3.46) | –1.17 (–4.33 to 1.98) | –0.48 (–3.85 to 2.89) | ||||
|
|
| |||||||||
|
|
| g | 0.3 | –0.02 | 0.15 | 0.14 | ||||
|
|
| .10 | .93 | .46 | .44 | |||||
|
|
| β (95% CI) | –2.64 (–5.82 to 0.53) | 0.14 (–3.10 to 3.38) | –1.19 (–4.35 to 1.96) | –1.32 (–4.69 to 2.06) | ||||
aPANAS: Positive and Negative Affect Schedule.
biTAU: improved treatment as usual.
cHLP: healthy lifestyle program.
dg: Hedge’s effect size measure.
eβ: regression coefficient.
fMP: mindfulness program.
gPAPP: positive affect promotion program.
hStatistically significant values (P<.05) are shown in italics.